This warrants further investigation of the clinical potential of anti-IL-1R7 for treating patients with MAS, MAS-like clinical manifestations of COVID-19, and other IL-18-mediated inflammatory diseases. This evidence concerns the gene IL18 and macrophage activation syndrome.